Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205-7199, USA.
J Pharmacol Exp Ther. 2010 Dec;335(3):728-34. doi: 10.1124/jpet.110.172247. Epub 2010 Sep 21.
Drug-elicited head-twitch behavior is a useful model for studying hallucinogen activity at 5-HT(2A) receptors in the mouse. Chemically diverse compounds active in this assay yield biphasic dose-effect curves, but there is no compelling explanation for the "descending" portion of these functions. A set of experiments was designed to test the hypothesis that the induction of head-twitch behavior is mediated by agonist actions at 5-HT(2A) receptors, whereas the inhibition of head-twitch behavior observed at higher doses results from competing agonist activity at 5-HT(2C) receptors. The effects of the phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) on head-twitch behavior were studied over a range of doses in the mouse, generating a characteristic biphasic dose-response curve. Pretreatment with the selective 5-HT(2A) antagonist (+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol (M100907) shifted only the ascending limb of the DOI dose-effect function, whereas pretreatment with the nonselective 5-HT(2A/2C) antagonist 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione (ketanserin) produced a parallel shift to the right in the DOI dose-response curve. Administration of the 5-HT(2C) agonist S-2-(chloro-5-fluoro-indol-l-yl)-1-methylethylamine (Ro 60-0175) noncompetitively inhibited DOI-elicited head-twitch behavior across the entire dose-effect function. Finally, pretreatment with the selective 5-HT(2C) antagonists 6-chloro-5-methyl-1-[(2-[2-methylpyrid-3-yloxy]pyrid-5yl)carbamoyl]indoline (SB242084) or 8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulfonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4,5]decane-2,4-dione hydrochloride (RS 102221) did not alter DOI-elicited head-twitch behavior on the ascending limb of the dose-response curve but shifted the descending limb of the DOI dose-response function to the right. The results of these experiments provide strong evidence that DOI-elicited head-twitch behavior is a 5-HT(2A) agonist-mediated effect, with subsequent inhibition of head-twitch behavior being driven by competing 5-HT(2C) agonist activity.
药物诱发的头部抽搐行为是研究 5-羟色胺(2A)受体在小鼠中致幻剂活性的有用模型。在该测定中具有活性的化学结构多样的化合物产生双相剂量效应曲线,但对于这些功能的“下降”部分没有令人信服的解释。设计了一组实验来测试以下假设:头部抽搐行为的诱导是由 5-HT(2A)受体的激动剂作用介导的,而在较高剂量下观察到的头部抽搐行为抑制是由于 5-HT(2C)受体的竞争性激动剂活性所致。在小鼠中,研究了苯乙胺致幻剂 R(-)-2,5-二甲氧基-4-碘苯丙胺(DOI)在一系列剂量下对头部抽搐行为的影响,产生了特征性的双相剂量反应曲线。用选择性 5-HT(2A)拮抗剂 (+)-(2,3-二甲氧基苯基)-1-[2-(4-氟苯乙基)]-4-哌啶甲醇(M100907)预处理仅使 DOI 剂量效应函数的上升支移位,而用非选择性 5-HT(2A/2C)拮抗剂 3-{2-[4-(4-氟苯甲酰基)哌啶-1-基]乙基}喹唑啉-2,4(1H,3H)-二酮(酮色林)预处理则使 DOI 剂量反应曲线向右平行移位。5-HT(2C)激动剂 S-2-(氯-5-氟-吲哚-1-基)-1-甲基乙基胺(Ro 60-0175)的给药非竞争性地抑制了整个 DOI 诱发的头部抽搐行为剂量效应功能。最后,用选择性 5-HT(2C)拮抗剂 6-氯-5-甲基-1-[[2-[2-甲基吡啶-3-基氧基]吡啶-5-基]氨基甲酰基]吲哚啉(SB242084)或 8-[5-(2,4-二甲氧基-5-(4-三氟甲基苯磺酰胺基)苯基)-5-氧戊基]-1,3,8-三氮杂螺[4,5]癸烷-2,4-二酮盐酸盐(RS 102221)预处理不会改变 DOI 诱发的头部抽搐行为在剂量反应曲线的上升支上,但使 DOI 剂量反应曲线的下降支向右移位。这些实验的结果提供了强有力的证据,证明 DOI 诱发的头部抽搐行为是 5-HT(2A)激动剂介导的效应,随后的头部抽搐行为抑制是由竞争性 5-HT(2C)激动剂活性驱动的。